Skip to main content
. 2015 Apr 21;21(15):4644–4651. doi: 10.3748/wjg.v21.i15.4644

Table 2.

Virologic and histologic efficacy at week 48 among treated patients with evaluable hepatic hepatitis B virus DNA pairs

Week 48 efficacy (NC = M) ETV (n = 159) LAM (n = 146)
Serum HBV DNA, mean ± SE, change from baseline log10 IU/mL -6.85 ± 0.16 -5.30 ± 0.22
Knodell necroinflammatory score, mean ± SE change from baseline -3.4 ± 0.26 -3.0 ± 0.29
Ishak fibrosis score, mean ± SE change from baseline -0.5 ± 0.08 -0.3 ± 0.08

NC = M: Non-completer = missing; ETV: Entecavir; LAM: Lamivudine.